[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100221601":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":21,"responsibleParty":26,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":10,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":34,"minAge":10,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":42,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":55},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"E2020",null,[12],"Drug: Donepezil Hydrochloride",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Donepezil Hydrochloride","Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.",[9],[20],"Aricept",[22],{"facility":10,"status":10,"city":23,"state":10,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Multiple Locations","Japan","JP",{"type":27,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100221601","post-marketing-surveillance-of-donepezil-hydrochloride-investigation-of-the-safety-and-effectiveness-of-combination-therapy-of-donepezil-hydrochloride-and-memantine-hydrochloride-in-patients-with-alzheimers-disease-100221601",false,"NCT02162251","Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease","Inclusion criteria:\n\nPatients diagnosed with Alzheimer's Disease who are to be administered both donepezil hydrochloride and memantine hydrochloride in clinical practice.\n\nExclusion criteria:\n\nPatients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.","ALL",{"count":36,"type":37},3482,"ACTUAL","OBSERVATIONAL","To investigate the safety and effectiveness about administration of both donepezil hydrochloride and menatine hydrochloride in patients with Alzheimer's Disease in clinical practice.",[41],"Alzheimer's Desease",[43,44],"Alzheimer's Disease","donepezil hydrochloride","COMPLETED","2018-09-06",{"date":48,"type":37},"2018-09-07",{"date":50,"type":37},"2013-06-01",{"date":52,"type":37},"2016-04-15",{"name":54,"class":6},"Eisai Co., Ltd.",1]